Kura Oncology
KURA
66 hedge funds and large institutions have $290M invested in Kura Oncology in 2017 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 3 closing their positions.
733% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 3
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
189% more capital invested
Capital invested by funds: $101M → $290M (+$190M)
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
50% more funds holding
Funds holding: 44 → 66 (+22)
19.62% more ownership
Funds ownership: 50.51% → 70.13% (+20%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$16.4M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$16.3M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$12.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.17M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.02M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.15M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$1.84M |
| 4 |
MA
Minerva Advisors
Bala Cynwyd,
Pennsylvania
|
-$577K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$217K |
KURA Hedge Fund Activity: Q3 2017 in Review
66 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q3 2017, worth a combined $290M — up 189% from $101M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KURA positions and 3 closed out — a net gain of 22 holders — while 25 added to existing stakes and 10 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $16.4M. The largest seller was Morgan Stanley, cutting an estimated $5.02M.
- 66 institutional investors held Kura Oncology (KURA) as of Q3 2017, up from 44 in Q2 2017.
- Funds reported $290M of Kura Oncology stock for Q3 2017, up 189% quarter-over-quarter.
- 25 funds opened new Kura Oncology positions in Q3 2017 and 3 closed out, a net change of +22 holders.
- The largest Kura Oncology buyer in Q3 2017 was Great Point Partners, an estimated $16.4M added.
- The largest Kura Oncology seller in Q3 2017 was Morgan Stanley, an estimated $5.02M sold.
Based on aggregated 13F filings for Q3 2017.